Refine by
Drug Response Articles & Analysis
64 news found
They also influence angiogenesis, tumour mechanical properties, drug access and therapeutic response. Recent studies have also revealed CAFs' crucial role in modulating the immune system. ...
Through this program, investigators or technology transfer offices with potential oncology drug candidates, in the early discovery or development phases, can submit their application to POAI for consideration. The POAI platform provides data (wet lab and active ML modeling) back to researchers based on access to an otherwise unreachable number of primary patient ...
Yang, L., et al (2024) introduces LungVis 1.0, an AI-driven imaging platform integrating light sheet fluorescence microscopy (LSFM) and deep learning for mapping nanoparticle (NP) deposition across murine lungs. The research highlights the advantages of aerosol-based delivery methods over traditional liquid-based approaches, emphasizing the uniformity of NP deposition in distal alveolar ...
The high failure rate of cardiovascular clinical trials (e.g., 11% of Phase II failure between 2008-11) indicates that there is an unmet need for more focused approaches, including personalized drug discovery for specific patient groups or even for rare genetic diseases, i.e., orphan drug market. Cardiovascular safety liabilities remain the major cause of costly ...
Pak told the audience the microfluidic device can keep biopsied cancer cells alive for three days in a simulated natural environment that enables scientists to measure their behavior and response to multiple drug combinations. Pak said she has funded development of the technology through $4.3 million in non-dilutive research grants, and LynxBio is now in the ...
“But in many instances, the Cellworks Platform has the ability to predict the human clinical response to drug candidates years earlier than traditional development pipelines. By predicting human clinical response much earlier in the drug development cycle, we can help pharmaceutical companies shave years off ...
“This study demonstrates the power of using Cellworks personalized therapy biosimulation to gain insight into individual patient mutanome, drug resistance pathways and novel biomarkers that determine their drug response and resistance to better inform treatment decisions for MDS ...
Drug therapy is one of the major modalities for cancer treatment. However, drug resistance may reveal whether it is chemotherapy drugs, targeted drugs, or immunotherapy drugs. ...
This strategic trial design follows a Type B meeting with the U.S. Food and Drug Administration and observed dose-dependent responses in a prior Phase 1/2b study assessing a range of doses. ...
(KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data of PMC-309, one of the Company’s first immuno-oncology drug candidates, at SITC (Society for Immunotherapy of Cancer) Annual Meeting taking place November 8-12 in Boston. ...
The first phase of the contract, which provides approximately $6 million to complete activities through the initial phase 1 study, coincides with grant support from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health. The new award builds on an existing partnership between Enalare Therapeutics and the BARDA DRIVe ReDIRECT (Repurposing ...
Immediate applications of Lifespin’s commercial services, which leverages access to Lifespin’s proprietary software and database, include quality control for synthetic/natural compounds, quantitative profiling of metabolites in liquid samples, monitoring of drug responses and organ-specific metabolic phenotyping, and precision nutrition to therapeutic ...
About PARIS® Test The PARIS® Test is a next generation diagnostic test that predicts drug responses by screening a broad panel of cancer drugs in patient-derived live tumor models by utilizing robotics, proprietary algorithms, and computational tools. ...
“The power of SEngine’s PARIS® platform to improve patient outcomes by providing oncologists individual drug effectiveness rankings as well as the innovation of new drugs will continue to propel SEngine ...
“This study will provide many important outcomes, giving patients and their physicians insight into the cancer’s response to various drugs from a screening panel, eventually helping clinical and treatment ...
ByxCures
This Phase I-II study relates to the Investigational New Drug (IND) application for the use of ALM-488 in head and neck surgery. ...
“Pharmaceutical formulation development is an indispensable step that makes the new drug substance being discovered gradually develop into a commercial drug product,” commented a senior scientist from CD Formulation. The scientist responsible for drug formulation must determine the most appropriate administration ...
Included in her reporting responsibilities were clinical development, clinical operations, clinical pharmacology, biometrics, translational research, program management and medical affairs. ...
ByBayer AG
The project aims to advance the discovery of peptide therapeutic candidates including the most challenging of drug targets by improving overall process efficiency whilst reducing the risk and associated costs. ...
“This study confirmed that there are many dysregulated signaling pathways responsible for hallmark behaviors of cancer and variable drug response in gastroesophageal adenocarcinoma patients,” said Dr. ...